MOTS-c: Mechanism, Research, and Regulatory Status

MOTS-c is the only peptide known to be encoded within mitochondrial DNA (specifically the 12S rRNA gene). All other peptides are encoded by nuclear DNA. This makes MOTS-c a founding member of an entirely new class of intercellular signals, the mitochondrial-derived peptides (MDPs). It also points to a previously unrecognized signaling axis between mitochondrial function and whole-body metabolism. Its AMPK activation mechanism via the folate cycle is also distinct from any other known peptide.

MOTS-c activates AMPK through the folate one-carbon cycle by inhibiting ATIC (an enzyme in purine synthesis) and causing AICAR accumulation. AICAR is a known direct AMPK activator. AMPK activation drives the same metabolic cascades triggered by exercise: increased glucose transporter 4 (GLUT4) translocation to the plasma membrane, enhanced fatty acid oxidation via CPT1 upregulation, mitochondrial biogenesis via PGC-1α, and mTORC1 suppression. Human studies show plasma MOTS-c rises during aerobic exercise and correlates with VO2max.

As of early 2026, MOTS-c has not completed published human Phase 1 clinical trials focused on efficacy. Early-stage human pharmacokinetic and safety investigations were initiated by CohBar Inc. (which has since restructured), but published Phase 1 data are limited. The bulk of the evidence base is preclinical (rodent models) and observational human studies measuring endogenous MOTS-c levels in response to exercise or in longevity cohorts.

Reconstitute lyophilized MOTS-c with bacteriostatic water or sterile saline. MOTS-c is a 16 amino-acid peptide without disulfide bonds and dissolves readily. Typical research concentration: 1–5 mg/mL. Solution should be clear and colorless. Store reconstituted solution at 2–8°C for up to 28–30 days. Lyophilized powder: −20°C in desiccated, sealed vials for up to 24 months.

Circulating MOTS-c levels decline progressively with age and with metabolic disease (obesity, T2D). Cross-sectional studies show centenarians and long-lived individuals have significantly higher MOTS-c than age-matched controls. This has led to the hypothesis that MOTS-c is part of a mitochondria-to-nucleus retrograde signaling axis that helps maintain metabolic health during aging. Exogenous MOTS-c administration in aged animal models restores skeletal muscle glucose uptake and mitochondrial function to near-youthful levels.

AMPK (AMP-activated protein kinase) is the master energy sensor of cells. It is activated when cellular energy (ATP) is depleted or when AICAR accumulates. AMPK activation drives a broad shift from building to breaking down: it increases glucose uptake, stimulates fatty acid oxidation, promotes mitochondrial biogenesis, inhibits fatty acid and cholesterol synthesis, and suppresses mTOR (which reduces protein synthesis and promotes autophagy). Together these effects improve insulin sensitivity, reduce fat mass, and enhance mitochondrial capacity, closely phenocopying exercise training.

Humanin (another mitochondrial-derived peptide from the 16S rRNA region) and MOTS-c are part of the same MDP class and may have complementary or additive effects in metabolic and cytoprotective research. Humanin primarily signals through a receptor complex involving CNTFR/IL-6ST and has demonstrated cytoprotective effects in neuronal and cardiac models. Researchers studying mitochondrial health and aging often examine both MDPs in parallel. Additionally, compounds that activate PGC-1α (like AICAR itself) or mitophagy may have synergistic mechanistic interactions.

MOTS-c is not currently on the WADA prohibited list as of the 2024 prohibited list. It is an endogenous peptide whose exogenous counterpart has not yet been detected in anti-doping tests. As a novel compound with no approved pharmaceutical use, it occupies a regulatory grey zone: not explicitly prohibited, but not approved. Researchers should monitor evolving regulatory guidance as the compound gains research attention.